Immuneering Corp. (IMRX)
4.615
-0.16
(-3.45%)
USD |
NASDAQ |
Sep 09, 16:00
4.615
0.00 (0.00%)
After-Hours: 16:48
Immuneering Enterprise Value : 162.99M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 162.99M |
| September 04, 2026 | 165.57M |
| September 03, 2026 | 179.81M |
| September 02, 2026 | 178.51M |
| September 01, 2026 | 167.52M |
| August 31, 2026 | 176.57M |
| August 28, 2026 | 176.57M |
| August 27, 2026 | 190.81M |
| August 26, 2026 | 186.92M |
| August 25, 2026 | 192.10M |
| August 24, 2026 | 188.87M |
| August 21, 2026 | 196.63M |
| August 20, 2026 | 193.39M |
| August 19, 2026 | 198.57M |
| August 18, 2026 | 179.16M |
| August 17, 2026 | 191.45M |
| August 14, 2026 | 181.10M |
| August 13, 2026 | 190.16M |
| August 12, 2026 | 181.75M |
| August 11, 2026 | 164.28M |
| August 10, 2026 | 146.81M |
| August 07, 2026 | 145.52M |
| August 06, 2026 | 142.28M |
| August 05, 2026 | 137.75M |
| August 04, 2026 | 138.40M |
| Date | Value |
|---|---|
| August 03, 2026 | 123.52M |
| July 31, 2026 | 120.93M |
| July 30, 2026 | 127.40M |
| July 29, 2026 | 116.08M |
| July 28, 2026 | 128.05M |
| July 27, 2026 | 135.81M |
| July 24, 2026 | 133.23M |
| July 23, 2026 | 137.75M |
| July 22, 2026 | 142.93M |
| July 21, 2026 | 142.28M |
| July 20, 2026 | 131.29M |
| July 17, 2026 | 153.93M |
| July 16, 2026 | 162.99M |
| July 15, 2026 | 187.57M |
| July 14, 2026 | 190.81M |
| July 13, 2026 | 187.57M |
| July 10, 2026 | 184.34M |
| July 09, 2026 | 200.51M |
| July 08, 2026 | 211.51M |
| July 07, 2026 | 183.69M |
| July 06, 2026 | 186.28M |
| July 02, 2026 | 189.51M |
| July 01, 2026 | 180.46M |
| June 30, 2026 | 176.57M |
| June 29, 2026 | 173.72M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Regeneron Pharmaceuticals, Inc. | 78.49B |
| ACADIA Pharmaceuticals, Inc. | 3.865B |
| Alnylam Pharmaceuticals, Inc. | 34.46B |
| Anika Therapeutics, Inc. | 268.42M |
| Savara, Inc. | 993.23M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.27M |
| Total Expenses (Quarterly) | 17.27M |
| EPS Diluted (Quarterly) | -0.2669 |
| Earnings Yield | -22.35% |
| Normalized Earnings Yield | -22.35 |